Astellas, Evopoint Ink Deal for CLDN18.2 ADC XNW27011
Agreement grants Astellas exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 XNW27011 has demonstrated encouraging monotherapy efficacy in an ongoing Phase 1/2 study...